Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

insulin aspart

- PMLiVE

Eli Lilly to expand injectable manufacturing capacity with new $2.5bn facility in Germany

The site is expected to be operational in 2027 and will employ up to 1,000 highly skilled workers

- PMLiVE

Novo Nordisk to buy KBP’s hypertension drug ocedurenone for up to $1.3bn

An estimated 1.28 billion adults aged 30 to 79 years worldwide have hypertension

- PMLiVE

Sanofi partners with AI specialist BioMap in deal worth more than $1bn

The strategic collaboration is aimed at accelerating drug discovery for biotherapeutics

- PMLiVE

Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn

About ten million people worldwide are affected by inflammatory bowel disease

- PMLiVE

Sanofi enters agreement with Janssen to develop E. coli vaccine candidate

Extraintestinal pathogenic E. coli is a leading cause of sepsis, particularly in older adults

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

- PMLiVE

Gilead’s Veklury recommended by CHMP for COVID-19 in patients with hepatic impairment

If approved, Veklury would become the first COVID-19 antiviral authorised for use across all stages of liver disease

- PMLiVE

Sanofi and Ad Scientiam partner to assess MS disability progression

The study will evaluate the ability of MSCopilot to identify early signs of disability worsening

- PMLiVE

Novo Nordisk enters new research alliance for diabetes and cardiometabolic diseases

The collaboration will focus on advancing three programmes across the next three years

- PMLiVE

Medscape’s Virtual Patient Simulation Makes a Significant Impact on Real-World Treatment Selection for T2D

An analysis of data using Real-World Outcomes showed that a virtual patient simulation had a significant effect on real-world treatment selection for T2D. The paper, published in JMIR Medical Education,...

Medscape Education Global

- PMLiVE

Novo Nordisk acquires Embark Biotech in deal worth over €470m

Novo gains access to Embark's lead asset targeting obesity and other cardiometabolic diseases

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links